ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 157.1 | 123.4 | 115.7 |
| Other income | 1.1 | 0.5 | 0.8 |
| Total income | 158.2 | 124.0 | 116.4 |
| Profit before exceptional items & tax | 31.7 | 23.2 | 19.1 |
| Exceptional items | 0.0 | 0.8 | 0.0 |
| Profit before tax | 31.7 | 22.3 | 19.1 |
| Net profit | 25.3 | 16.0 | 14.5 |
| Operating margin | 20.0% | 18.0% | 16.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +74.50% |
|---|---|
| Net profit, quarter on quarter | +58.10% |
| Revenue, year on year | +35.80% |
BSE results filing, NSE: KPL. Figures extracted from the filing.
Kwality Pharmaceuticals Ltd: key numbers
- Share price
- ₹4,020.00
- Market cap
- ₹4,171 Cr
- Revenue (annual)
- ₹503.1 Cr
- Net profit (annual)
- ₹67.35 Cr
- P/E (TTM)
- 51.5×Sector 43.8×
- Promoter holding
- 54.86%+0.00% QoQ
- FII holding
- 2.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kwality Pharmaceuticals Ltd
All →Kwality Pharmaceuticals Investor Presentation: Key Takeaways
Q2FY27 revenue ₹181.2 Cr (+62% YoY, +12% QoQ), EBITDA ₹49.8 Cr (27.5% margin), PAT ₹29.0 Cr (16.0%). FY27 revenue guidance raised to ₹720+ Cr.
- Call
- Guides 43% growth
Kwality Pharmaceuticals Q2 FY27 Results: Net Profit ₹29 Cr, Up 105.7% YoY
Kwality Pharmaceuticals Ltd reported revenue from operations of ₹181.2 Cr (+63.1% YoY) and net profit of ₹29 Cr (+105.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹29 Cr · +105.7% YoY
Kwality Pharmaceuticals Board Meeting Date
Kwality Pharmaceuticals will hold a board meeting on November 12, 2026. The board will consider and approve unaudited financial results for the quarter and half-year ended September 2026.
Kwality Pharmaceuticals Business Update
Kwality Pharmaceuticals secured EU-GMP approval from Hungary for its Cephalosporin and Oncology facilities. This expands its EU-approved manufacturing footprint and positions it for global licensing opportunities.
Kwality Pharmaceuticals Other Announcement
Kwality Pharmaceuticals Ltd filed its shareholding pattern for the quarter ended September 30, 2026, as required by SEBI regulations.
Kwality Pharmaceuticals Capacity Expansion
Kwality Pharmaceuticals acquired 4 acres adjacent to its Amritsar plant to build a fully automated facility with 10+ production lines. Completion is targeted by Q4 FY2028 with full operations by Q2 FY2029.
- Execution
- Completion by Q4 FY2028; full operations by Q2 FY2029
- manufacturing production lines (injectable + oral solid + ophthalmic)
- 10 production lines